CAR T cells reach clinical milestone in prostate cancer

Armored CAR T cells show early signs of clinical activity in patients with castration-resistant prostate cancer, paving the way for further development and optimization.

Saved in:
Bibliographic Details
Published inNature medicine Vol. 28; no. 4; pp. 635 - 636
Main Authors Tschernia, Nicholas P., Norberg, Scott M., Gulley, James L.
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.04.2022
Nature Publishing Group
Subjects
Biomedical and Life Sciences
Biomedicine
Cancer Research
Castration
Humans
Immunotherapy, Adoptive
Infectious Diseases
Lymphocytes
Lymphocytes T
Male
Metabolic Diseases
Molecular Medicine
Neurosciences
News & Views
news-and-views
Optimization
Prostate cancer
Prostatic Neoplasms - therapy
Receptors, Chimeric Antigen - genetics
T-Lymphocytes
Online AccessGet full text

Cover

More Information
Summary:Armored CAR T cells show early signs of clinical activity in patients with castration-resistant prostate cancer, paving the way for further development and optimization.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:1078-8956
1546-170X
DOI:10.1038/s41591-022-01742-1